The record · Mechanism & trials
PT-141 research: how the melanocortin agonist works and what the trials found.
Mechanism, the two pivotal Phase 3 trials, the mechanistic neuroimaging, and the most recent literature — read as a cited ledger.
The short version
PT-141 research is unusually concrete because the compound is an FDA-approved drug with real human-trial data behind it. The core finding: bremelanotide works in the brain, not in blood flow. It activates melanocortin receptors (brain switches that, among other jobs, regulate sexual motivation) in the hypothalamus, and through that route it raises sexual desire [1][5].
The biggest studies are two matched Phase 3 trials in 1,267 women, which found a real but modest improvement in desire [3], plus a year-long follow-up that showed the effect held and that nausea was the main side effect [4]. A 2022 brain-imaging study showed the effect from inside the brain [5]. The sections below set out the mechanism, the key trials, and the most recent research, each finding cited to its source.
Mechanism: a central melanocortin agonist
PT-141 is a synthetic analogue of alpha-MSH (alpha-melanocyte-stimulating hormone — a natural signaling peptide cleaved from a precursor protein called POMC) [1]. It activates the melanocortin-4 receptor (MC4R) and, secondarily, MC3R — receptors concentrated in the hypothalamus and limbic system [1]. By stimulating MC4R in circuits such as the medial preoptic area (a hypothalamic region tied to sexual motivation), it is thought to engage dopamine pathways that govern desire and arousal [1].
This is the mechanistic dividing line from the older erectile-dysfunction drugs. A PDE-5 inhibitor acts peripherally on vascular smooth muscle to improve blood flow; PT-141 acts centrally, on the neural circuitry of sexual motivation [1]. Animal work supports the central account: systemic administration produced erections in rats and nonhuman primates and activated hypothalamic neurons (measured as increased c-Fos), and in male research it produced rapid dose-dependent erectile activity [1].
PT-141 peptide: structure and identity
The PT-141 peptide is a cyclic heptapeptide lactam — a ring of seven amino acids closed by a bridge between two side chains — with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH [1]. Its molecular weight is 1025.2 Da, its formula is C50H68N14O10, and its CAS number is 189691-06-3 [1]. The cyclic ring confers greater stability than linear melanocortin peptides, which is part of why it became a viable drug [1].
Its international nonproprietary name is bremelanotide, and it reached the market under NDA 210557 in 2019 [7]. A 2020 analysis of FDA peptide and oligonucleotide approvals situates it within the strong 2019 cohort of peptide drug approvals [10].
PT-141 for women: the pivotal evidence
The approval rests on the two RECONNECT Phase 3 trials, run as an identical pair in 1,267 premenopausal women with HSDD [3]. Bremelanotide 1.75 mg subcutaneous as-needed improved FSFI-desire by an integrated +0.35 (P<.001) and reduced FSDS-DAO desire distress by an integrated −0.33 (P<.001) versus placebo over 24 weeks; both coprimary endpoints were met in both trials [3]. The 52-week open-label extension in 684 women showed sustained efficacy and a stable safety profile [4].
The mechanism in women was imaged directly in 2022: in 31 premenopausal women with HSDD, MC4R agonism raised desire for up to 24 hours and altered task-based brain processing of erotic stimuli [5]. A review of female sexual-dysfunction treatment places bremelanotide specifically within the premenopausal-HSDD indication, distinct from off-label transdermal testosterone used in postmenopausal women [9].
PT-141 for men: investigational only
Research in men exists, but it has not produced an approval. Early studies found rapid dose-dependent erectile activity in men with erectile dysfunction, consistent with the central mechanism [1]. In June 2024, the developer announced a Phase 2 study of roughly 50 patients testing bremelanotide co-administered with a PDE-5 inhibitor in men who do not respond to PDE-5-inhibitor monotherapy, with a co-formulation IND and a potential Phase 3 planned [8].
This program is investigational: it has not been reviewed or approved for marketing [8]. Any use of PT-141 in men today is off-label or research-grade, not an FDA-approved indication [7].
The most recent research
The recent literature pulls in two directions, which is exactly why a balanced ledger is useful. On the supportive side, a 2026 systematic review and meta-analysis of female sexual-dysfunction treatments reported that bremelanotide improved total FSFI plus the desire and arousal subscales across pooled trials [13]. On the critical side, Spielmans (2024) argues the effects are small and questions the outcome interpretation [12].
Preclinical work continues to refine the mechanism. A 2025 study in female Syrian hamsters found MC3R/MC4R mRNA concentrated in dopamine neurons of the ventral tegmental area, but neither dose of bremelanotide changed melanocortin-receptor expression there, and the drug did not enhance sexual reward in a place-preference test — suggesting it does not act on the VTA reward circuit [6]. The honest reading: the central account holds, but the precise circuitry is still being mapped.